Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

About this update from Kymera Therapeutics, Inc.

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader, will be featured in a late breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting being held May 13-16, in Chicago, IL, and an oral presentation at the American Thoracic Society (ATS) Respiratory Innovation Summit being held May 15-16, in Orlando, FL. “These presentations are an important opportunity for us to engage with the medical community and discuss the potential of KT-621 to expand patient access to a novel oral systemic therapy across a range of chronic immuno-inflammatory diseases, including atopic dermatitis and asthma, where treatment options remain limited,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “The depth and consistency of the data we’ve reported to date, including robust STAT6 degradation and downstream modulation of disease-relevant markers of Type 2 inflammation, continue to strengthen our confidence in this approach and its potential to improve patient outcomes and ease the burden of disease with a convenient, once daily oral therapy.” The Company previously reported results from the KT-621 BroADen Phase 1b trial demonstrating deep STAT6 degradation in blood and skin, reductions in Type 2 inflammatory biomarkers such as TARC, Eotaxin-3, IL-31, and FeNO, encouraging clinical activity, and a favorable safety profile. Additionally, KT-621 also showed early evidence of activity in asthma based on improvement in biomarkers and patient-reported outcome in AD patients with comorbid asthma, as highlighted in the ATS presentation. New data from the Phase 1b study presented at SID further characterize STAT6 degradation by KT-621 in the skin, demonstrating robust, com...

View stock analysis, news, and events for Kymera Therapeutics, Inc.